Comment
In this case report, the extra-ocular phenotype is characteristic of RCS. Conversely, the phenotype exhibited on the right eye has not been previously reported. Calcified keratopathy, which represents the first corneal defect ever documented in RCS, is probably consecutive to chronic renal failure with calcium phosphate disturbances. 4 The second intriguing ocular abnormality was the presence of spontaneous lens luxation. Interestingly, investigators have previously reported that patients with RCS may have joint abnormalities such as joint laxity. 2, 5 In this case, the child also suffered from joint laxity and had been operated on for bilateral hip dislocation. Therefore, we suggest the possibility that lens luxation could be part of a general disorder involving the connective tissue or elastic fibres of different types and locations. This original description stresses the importance of investigating potential cornea or lens damage in patients presenting with such a syndrome.
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The authors declare no conflict of interest. Conjunctival lymphomas typically result from a monoclonal B-cell proliferation and represent either localized disease or a systemic malignancy. 1 Most patients are over 60 years of age or are immunosuppressed. 1 Patients typically present with insidious onset of an asymptomatic, salmon-coloured, well-demarcated mass. Uncommonly, lymphoma may occur following treatment with immunosuppressive medications. 2 We present a case of conjunctival lymphoma that presented 4 years after treatment with cyclophosphamide. Although the association may be coincidental, our case emphasizes that physicians should be alert to the possibility of secondary malignancy occurring in the eye following systemic immunosuppression.
Case report
A 68-year-old man, with a history of sympathetic ophthalmia that occurred 6 years earlier, noticed a painless red mass in his right eye. Therapy for sympathetic ophthalmia included prednisone and a 6-month course of cyclophosphamide 50 mg/day. His past ocular history was otherwise notable for multiple intraocular surgeries in the right eye for cataract and open-angle glaucoma. On presentation, his visual acuity was 20/25 OU. Examination of the right conjunctiva revealed a salmon-coloured, vascularized mass from 1 o'clock to 3 o'clock ( Figure 1) . Fundus examination revealed a sunset glow appearance and chorioretinal scars bilaterally.
Biopsy revealed a diffuse lymphocytic stromal infiltrate (Figure 1b) . Most lymphocytes were enlarged, with variable cytoplasm, irregular nuclei, and intranuclear inclusions (Dutcher bodies). Immunophenotyping revealed strong CD20 and kappa light chain positivity. The histopathological diagnosis was a low-grade B-cell lymphoma that was mostly consistent with marginal zone lymphoma. This type of lymphoma is often referred to as mucosa-associated lymphoid tissue lymphoma. Treatment involves evaluation for systemic disease. Localized conjunctival lymphoma may be treated with radiotherapy, although some cases may be cured by local excision.
Comment
Long-term studies of patients treated with cyclophosphamide showed an increased risk for malignancy, including lymphomas. [2] [3] [4] Hoffman et al 2 observed a 2.4-fold overall increase in the incidence of malignancies, and an 11-fold greater incidence of systemic lymphomas in the general population. The risk appears to be dose-dependent, particularly with cumulative doses 450 g, but is also reported with lower doses, and may develop for up to 10 years. 5 Our patient received a total of 9 g. Potential mechanisms of malignancy include induced chromosomal alterations, altered immune-mediated anti-tumour surveillance, and increased susceptibility to oncogenic agents. 3 Although the possibility remains that the association was spurious, our report of conjunctival lymphoma following treatment with systemic cyclophosphamide is the first report of such a secondary ocular malignancy, and illustrates that physicians should be alert to the possibility of secondary malignancy occurring in the eye following systemic immunosuppression.
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